Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Cardiol
Asıl Yazarlar: Navar, Ann Marie, Taylor, Benjamin, Mulder, Hillary, Fievitz, Eugene, Monda, Keri L., Fievitz, Anna, Maya, Juan F., López, J. Antonio G., Peterson, Eric D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2017
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963012/
https://ncbi.nlm.nih.gov/pubmed/28973087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3451
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller